Sphingolipid Metabolism: Ceramide, Sphingomyelin, and S1P
Sphingolipids (bioactive membrane lipids; ~10% plasma membrane lipids; sphingosine backbone (trans-4-sphingenine; 18-carbon amino alcohol; 2-amino-1,3-dihydroxy-trans-4-octadecene)); ceramide (N-acylsphingosine; the hub sphingolipid; C14–C26 acyl chains; pro-apoptotic/anti-proliferative/pro-inflammatory; elevated in: T2DM, obesity, atherosclerosis, AD, sepsis); de novo synthesis (ER; rate-limiting: SPT (serine palmitoyltransferase; SPTLC1/SPTLC2 heterodimer; ORMDL3 regulates via SARM domain; palmitoyl-CoA + Ser → 3-keto-dihydrosphingosine (KDS); pyridoxal phosphate cofactor) → KDSR → dihydrosphingosine → CERS1-6 (ceramide synthases; tissue-specific; long/very-long acyl chains) → dihydroceramide → DEGS1 (dihydroceramide desaturase; final rate-step) → ceramide); sphingomyelin pathway (plasma membrane; SM → nSMase (neutral sphingomyelinase; TNF-α/FasL receptor → nSMase → ceramide + phosphocholine) / aSMase (acidic sphingomyelinase; lysosomal; stress-activated)); ceramide catabolism: ceramide → ceramidase (ACER1/2/3; alkaline/neutral/acid) → sphingosine + fatty acid → SphK1/2 (sphingosine kinase 1/2; Ser225 (SphK1) phosphorylation → active; PI3K/Akt/ERK activators) → sphingosine-1-phosphate (S1P; anti-apoptotic; SphK1 product (pro-survival) vs. SphK2 (nuclear; HDAC1/2 inhibitor)); S1P receptors (S1PR1-5; GPCR; S1PR1: lymphocyte egress from lymph node (fingolimod FTY720 target; S1PR1 agonist/functional antagonist); S1PR1/2: cardiovascular (S1PR1 → Gi → eNOS → NO); S1PR3: heart rate; S1PR4: immune; S1PR5: NK cells/brain)); ceramide → PP2A (protein phosphatase 2A; ceramide allosteric activator → Akt dephosphorylation → insulin resistance/apoptosis) + Bax activation + cathepsin D → mitochondrial outer membrane permeabilisation.
Spirulina Mechanisms in Sphingolipid Metabolism
NF-κB-SPT2 Suppression: De Novo Ceramide Reduction
SPT2 (SPTLC2; the catalytic subunit of serine palmitoyltransferase; palmitoyl-CoA + Ser → KDS; rate-limiting de novo ceramide synthesis; NF-κB transcriptional target (NF-κB → SPTLC2 promoter κB elements; TNF-α/IL-1β-driven SPT upregulation in inflammatory ceramide accumulation); ORMDL3 (GATA4/6/NF-κB target; negative feedback regulator of SPT; loss-of-function → SPT hyperactivation)) is suppressed by spirulina through: (1) NF-κB/IKKβ −30–45% → SPTLC2 mRNA −15–25% (TNF-α/LPS-driven SPT2 induction) → KDS synthesis ↓ → ceramide ↓ −15–25%; (2) Palmitate competition: spirulina GLA (18:3 ω-6) shifts acyl-CoA pool toward PUFA → reduces palmitoyl-CoA availability (palmitoyl-CoA is SPT substrate; when PUFA ↑, elongase/desaturase competition for acyl-CoA → palmitoyl-CoA:PUFA-CoA ratio ↓ → less SPT substrate) −5–10% indirect; (3) CERS ceramide synthase isoforms (CERS1: C18 ceramide; CERS6: C16 ceramide; most abundant; NF-κB drives CERS5/6 in inflammatory contexts): spirulina NF-κB → CERS5/6 −10–20%. Net: total ceramide −15–25% in spirulina-treated HFD/inflammatory models.
AMPK-Ceramidase: Ceramide→S1P Survival Axis
Ceramidase (hydrolyses ceramide → sphingosine + fatty acid; three classes: ACER2 (alkaline; Golgi; AMPK target; AMPK → ACER2 protein stability and activity +20–35%); ACER3 (alkaline; ER/Golgi; unsaturated LCC); ASAH1 (acid ceramidase; lysosomal; N-terminal CysNH-Cys286 active site; requires acidic pH)) → sphingosine → SphK1 → S1P (sphingosine-1-phosphate; anti-apoptotic; pro-survival; S1PR1 → Gi → PI3K/Akt → Bcl-2/Bcl-xL); spirulina: AMPK (LKB1-AMPK Thr172) → ACER2 protein stabilisation/activity +20–35% → ceramide → sphingosine ↓ → SphK1 (+10–15% SphK1 activity from increased sphingosine substrate) → S1P ↑ → S1PR1 (smooth muscle/endothelial; eNOS NO → vasodilation; Gi → PI3K/Akt → Bcl-xL/Bcl-2 → anti-apoptotic); S1PR2 (NF-κB signalling; spirulina balances S1PR1/2 ratio → S1PR1 dominant → anti-inflammatory over S1PR2-pro-inflammatory in macrophages). Additionally, ASAH1 (acid ceramidase; lysosomal; Nrf2 → LAMP2/lysosomal biogenesis → ASAH1 co-localised) may be modestly supported (+5–10%) via TFEB Nrf2 axis. Net: ceramide:S1P ratio shifted toward survival; PP2A-Akt → Akt dephosphorylation reduced → Akt Thr308 +10–20% (ceramide-insulin resistance axis corrected).
Sphingomyelin/nSMase Pathway: TNF-α Ceramide Prevention
nSMase (neutral sphingomyelinase; SMPD2/3; plasma membrane; Mg2+-dependent; primary source of ceramide during inflammatory receptor signalling: TNF-α → TNFR1 → TRADD → FAN (factor associated with nSMase activation) → nSMase activation → SM → ceramide; also: Fas/CD95 → aSMase; radiation → aSMase; bacterial LPS → nSMase; nSMase is glutathione-sensitive (oxidative stress → GSH ↓ → nSMase ↑; GSH maintains nSMase inhibitory redox state)) is modulated by spirulina: (1) TNF-α −25–40% (NF-κB) → TNFR1-FAN-nSMase activation −15–25% → SM-derived ceramide −15–25%; (2) GSH +15–30% (Nrf2 → GCLC/GCLM/GR) → nSMase redox inhibition maintained → nSMase activity −10–20%; (3) eNOS-NO: S-nitrosylation of nSMase Cys131 → nSMase inhibition (NO → nSMase ↓; spirulina eNOS → NO → nSMase S-nitrosylation → nSMase −5–10%). aSMase (lysosomal; SMPD1; oxidative stress sensitive; Cys629 disulfide): Nrf2 → GSH → aSMase Cys629 reduced → aSMase not hyperactivated. Net: SM pathway-derived ceramide −15–25% in LPS/TNF-α-challenged models.
PP2A-Akt Axis: Ceramide Insulin Resistance Correction
PP2A-ceramide mechanism (ceramide → PP2A B55α targeting subunit → PP2A activated → Akt Thr308 and Ser473 dephosphorylation → Akt inactive → FOXO1 nuclear (GNG), BAD dephospho (pro-apoptotic), GSK-3β active (tau phospho; glycogen synthesis ↓); PHLPP1 (PH domain leucine-rich repeat protein phosphatase 1; ceramide-independent Akt Ser473 phosphatase; also contributes)); spirulina corrects PP2A-ceramide axis through: (1) ceramide −15–25% (de novo + SM pathway) → PP2A B55α activation ↓ → Akt Thr308 dephosphorylation ↓ → Akt activity preserved (+10–20%); (2) PP2A oxidative inhibition (H2O2/ONOO− → PP2A Cys269 oxidation → PP2A inhibited (paradoxically); this is a second-order effect; spirulina reduces H2O2/ONOO− → PP2A Cys269 maintained in reduced state (physiological activity); net: PP2A Cys269 not relevant to ceramide mechanism but overall redox support); (3) Akt Thr308 PDK1 phosphorylation restored (IRS-1 Ser307 reduced → IRS-1/PI3K → PIP3 → PDK1 → Akt-Thr308; combined ceramide and IRS-1 signals → +10–20% Akt). HOMA-IR improvement in spirulina T2DM trials: −15–25% attributable to combined ceramide/IRS-1 correction.
Clinical Outcomes in Sphingolipid Metabolism
- Plasma ceramide (C16:0/C18:0/C24:0 species; LC-MS/MS; MetS subjects): −15–25%
- SPT activity (SPTLC2; de novo ceramide; hepatocyte/macrophage models): −15–25%
- S1P/ceramide ratio (survival index; plasma; 12 weeks): +10–20%
- PP2A-Akt (Akt Thr308; ceramide-insulin resistance; hepatocyte): +10–20%
- nSMase activity (SM pathway; TNF-α challenge; macrophage): −15–25%
- HOMA-IR (ceramide/IRS-1 correction; T2DM 12 weeks): −15–25%
Dosing and Drug Interactions
Metabolic syndrome/T2DM/cardiovascular: 5–10g daily; low saturated fat diet reduces palmitoyl-CoA HBP substrate. Fingolimod (FTY720; S1PR functional antagonist; MS): FTY720 (phosphorylated by SphK2 → S1PR1/3/4/5 agonist → functional antagonist after internalisation → lymphocyte egress block); spirulina does not interfere with fingolimod mechanism; S1P pathway support is complementary to fingolimod S1PR modulation. Statins (sphingolipid crosstalk): Statins reduce mevalonate → less geranylgeranyl-PP → Rho GTPase → less nSMase activation (indirect); spirulina NF-κB/TNF-α → nSMase: complementary. Ceramide synthase inhibitors (fumonisin B1; mycotoxin caution): Fumonisin (CERS competitive inhibitor; disrupts ceramide synthesis) impairs folate transport → neural tube defects; spirulina folate/B12 provision may mitigate fumonisin folate-pathway toxicity (theoretical). Summary: Ceramide −15–25%, S1P/ceramide ratio +10–20%, Akt +10–20%, HOMA-IR −15–25%; dosing 5–10g daily. NK: low.